News

26.04.2016

Start-up meeting associated with initiation of clinical studies of Ergoferon

Start-up meeting associated with initiation of two international multicenter double blind placebo-controlled randomized clinical studies of Ergoferon was carried out on April 7-8 in Sochi
28.01.2016

Laboratory of Influenza under Pasteur Institute and APcis carried out a study in cooperation with Materia Medica Holding.

The results of non-clinical study of a novel antiviral drug Anaferon for children
11.11.2015

Officials of Mexico National Institute of Pediatrics confirmed recommendations on Anaferon for children application for prevention and treatment of acute infectious respiratory diseases

The authors of recommendations and review article published in Revista de enfermedades infecciosas en Pediatría journal (Journal of infectious diseases in pediatrics)* are deputy director on medical studies José Luis Arredondo García and research officer of clinical study department Agustín Méndez Herrera.

28.07.2015

3rd Drug Discovery & Therapy World Congress

On July 21-25, 2015 Materia Medica Holding took part in 3rd n Drug Discovery & Therapy World Congress 2015 (DDTWC-2015) in Boston, USA.
14.05.2015

7 International Congress of Antibodies

Materia Medica took part in 7th Annual International Congress of Antibodies, ICA-2015 (Chinese Peoples Republic, April 25-28, 2015).
20.12.2013

Antiviral drug ANAFERON became the laureate of Premium “Brand of the Year No. 1 in Russia” in Kremlin!

On December 14, 2013 the State Kremlin Palace held the 16th ceremony honouring the laureates of “Brand No. 1 in Russia”.
05.06.2013

23rd Congress on Clinical Microbiology and Infectious Diseases (Berlin)

On April 27-30, Congress on Clinical Microbiology and Infectious Diseases took place in Berlin convening more than 10 thousand global experts. The Congress is the most large-scale global event related to infectious diseases.
24.04.2013

GMP certificate

GMP certificate
22.04.2013

ISO 9001-2011 (ISO 9001:2008) Quality Management Systems - Audited and Certified

ISO 9001-2011 (ISO 9001:2008) Quality Management Systems - Audited and Certified
27.12.2012

Pharmaceutical company OOO "NPF "Materia Medica Holding" has obtained GMP certificates from Slovakia and Ukraine

In October 2012, manufacturing unit of OOO "NPF "Materia Medica Holding" located in Chelyabinsk successfully completed the audit of State Administrations of Ukraine and Slovakia.
18.02.2016

Four extensive multicenter randomized trials have been completed which evaluated the safety and efficacy of two release-active drugs – liquid Ergoferon and Rengalin – in children and adults with acute respiratory infections (ARIs).

Ergoferon is a new antiviral compound with anti-inflammatory and antihistamine effects which is indicated for use in combination treatment of viral ARIs, including the flu, and is essentially composed of release-active anti-IFN-gamma, anti-histamine and anti-CD4 antibodies. Two placebo-controlled efficacy and safety studies of liquid Ergoferon involved 648 participants with viral ARIs recruited by 30 clinical centers.
24.12.2015

Dear friends! Materia Medica Holding Company wishes you a Merry Christmas and a Happy New Year 2016!

12.08.2015

Materia Medica expands manufacturing unit

16.06.2015

First Russian GMP certificate

03.04.2014

Opening Research Laboratory - breakthrough in comprehensive studies and manufacturing developments

At the beginning of 2014 OOO “NPF "Materia Medica Holding” opened the first research laboratory of its own.
14.10.2013

Anaferon for children has been recognized by European Respiratory Society as an effective drug for the treatment of recurring viral upper respiratory infections in children with bronchial asthma

Annual Congress of European Respiratory Society 2013 (ERS 2013) held on September 7-11, 2013 in Barcelona, presented the results of a randomized double-blind placebo-controlled study of efficacy of Anaferon for children in prevention and therapy of recurring viral upper respiratory infections in children with bronchial asthma.
08.05.2013

The trial of Anaferon for children in Vietnam

The trial of Anaferon for children in Vietnam.
23.04.2013

Impaza medicine is registered in Mexico

Impaza medicine is registered in Mexico.
15.04.2013

Impaza has been authorized in Mexico

The drug for the treatment of erectile dysfunction Impaza has been authorized in Mexico
06.02.2012

Sensational findings on antiviral efficacy of Anaferon for children according to Antiviral Research Journal of International Society on Antiviral Research

The results of the study of antiviral activity of Anaferon for children on experimental model of swine influenza have been published.